We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allscripts' iPro Anesthesia to be Administered by SingHealth
Read MoreHide Full Article
Allscripts Healthcare Solutions (MDRX - Free Report) recently partnered with Singapore’s largest public healthcare group, SingHealth, with a view to implement iPro Anesthesia. iPro Anesthesia is a cloud-based, mobile Anesthesia Information Management System (AIMS) designed by practicing anesthesiologists to produce a complete, compliant and legible anesthesia record. Its multi-modular platform is designed to fit the needs of any hospital size or specialty center.
Notably, following the announcement, the company’s shares have inched up 0.8% to eventually close at $12.60. In the past year, Allscripts’ shares have rallied 10.4%, outperforming the industry’s rally of 5.4%. We believe such developments will provide Allscripts a competitive edge in the healthcare IT (HCIT) space.
SingHealth is a healthcare group with more than 40 clinical specialties, a network of community hospitals and primary care clinics.
Per management, using APIs to exchange data with an electronic health record (EHR) is a good step toward better interoperability.
Allscripts’ EHR Collaborations
The Singapore-based comprehensive medical care provider, SingHealth, had earlier selected Allscripts’ flagship Sunrise suite of solutions, and successfully leveraged the company’s open platform and application programming interfaces (APIs). Moreover, even in the past, hospitals in Singapore had experienced success in using Allscripts Open APIs with Allscripts Sunrise.
Allscripts Sunrise is a fully integrated platform that connects all clinical and financial aspects of a hospital or health system for inpatient and outpatient care.
For instance, Integrated Health Information Systems started using Allscripts Open APIs with Sunrise, while California-based NantHealth uses Allscripts’ API that validates and saves the data directly to the Sunrise patient record.
Furthermore, Allscripts eyes further expansion of its footprint with the Singapore Ministry of Health later in 2018, implementing Allscripts Sunrise clinicals at the 14,000-bed SengKang General and Community Hospitals system.
Moreover, in the last reported quarter, Allscripts announced that it is joining forces with the California-based rideshare company, Lyft, to incorporate non-emergency transportation directly into the physician's workflow. The integration of Lyft's proprietary APIs and Allscripts' open platform into Allscripts Sunrise EHR will enable clinicians to order the Lyft services for patients.
Market Prospects
Per a research by MarketsandMarkets, the HCIT market is expected to reach $280.25 billion by 2021 from $134.25 billion in 2016, at a CAGR of 15.9%. Factors such as the growing need to manage regulatory compliance through healthcare IT solutions, government support for healthcare IT solutions and rising need to curtail escalating healthcare costs drive the market.
Zacks Ranks & Key Picks
Allscripts currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Abiomed, Inc. , Genomic Health Inc. and Varian Medical Systems, Inc. .
Genomic Health has an expected earnings growth rate of 187.5% and a Zacks Rank #1.
Varian Medical has a projected long-term earnings growth rate of 8%. The stock carries a Zacks Rank #2 (Buy).
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Allscripts' iPro Anesthesia to be Administered by SingHealth
Allscripts Healthcare Solutions (MDRX - Free Report) recently partnered with Singapore’s largest public healthcare group, SingHealth, with a view to implement iPro Anesthesia. iPro Anesthesia is a cloud-based, mobile Anesthesia Information Management System (AIMS) designed by practicing anesthesiologists to produce a complete, compliant and legible anesthesia record. Its multi-modular platform is designed to fit the needs of any hospital size or specialty center.
Notably, following the announcement, the company’s shares have inched up 0.8% to eventually close at $12.60. In the past year, Allscripts’ shares have rallied 10.4%, outperforming the industry’s rally of 5.4%. We believe such developments will provide Allscripts a competitive edge in the healthcare IT (HCIT) space.
SingHealth is a healthcare group with more than 40 clinical specialties, a network of community hospitals and primary care clinics.
Lately, in a bid to significantly expand its coveted FollowMyHealth platform, Allscripts acquired Florida-based HealthGrid Holding Company. (Read more: Allscripts Acquires HealthGrid to Improve Patient Outcome).
Per management, using APIs to exchange data with an electronic health record (EHR) is a good step toward better interoperability.
Allscripts’ EHR Collaborations
The Singapore-based comprehensive medical care provider, SingHealth, had earlier selected Allscripts’ flagship Sunrise suite of solutions, and successfully leveraged the company’s open platform and application programming interfaces (APIs). Moreover, even in the past, hospitals in Singapore had experienced success in using Allscripts Open APIs with Allscripts Sunrise.
Allscripts Sunrise is a fully integrated platform that connects all clinical and financial aspects of a hospital or health system for inpatient and outpatient care.
For instance, Integrated Health Information Systems started using Allscripts Open APIs with Sunrise, while California-based NantHealth uses Allscripts’ API that validates and saves the data directly to the Sunrise patient record.
Furthermore, Allscripts eyes further expansion of its footprint with the Singapore Ministry of Health later in 2018, implementing Allscripts Sunrise clinicals at the 14,000-bed SengKang General and Community Hospitals system.
Moreover, in the last reported quarter, Allscripts announced that it is joining forces with the California-based rideshare company, Lyft, to incorporate non-emergency transportation directly into the physician's workflow. The integration of Lyft's proprietary APIs and Allscripts' open platform into Allscripts Sunrise EHR will enable clinicians to order the Lyft services for patients.
Market Prospects
Per a research by MarketsandMarkets, the HCIT market is expected to reach $280.25 billion by 2021 from $134.25 billion in 2016, at a CAGR of 15.9%. Factors such as the growing need to manage regulatory compliance through healthcare IT solutions, government support for healthcare IT solutions and rising need to curtail escalating healthcare costs drive the market.
Zacks Ranks & Key Picks
Allscripts currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Abiomed, Inc. , Genomic Health Inc. and Varian Medical Systems, Inc. .
Abiomed has a long-term earnings growth rate of 27%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Genomic Health has an expected earnings growth rate of 187.5% and a Zacks Rank #1.
Varian Medical has a projected long-term earnings growth rate of 8%. The stock carries a Zacks Rank #2 (Buy).
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>